References
- van der Linden SM, Valkenburg HA, de Jongh BM, Cats A. The risk of developing ankylosing spondylitis in HLA-B27 positive individuals: a comparison of relatives of spondylitis patients with the general population. Arthritis Rheum 1984;27:241-249. https://doi.org/10.1002/art.1780270301
- Brophy S, Hickey S, Menon A, Taylor G, Bradbury L, Hamersma J, et al. Concordance of disease severity among family members with ankylosing spondylitis? J Rheumatol 2004;31:1775-1778.
- Wellcome Trust Case Control Consortium; Australo-Anglo-American Spondylitis Consortium (TASC); Burton PR, Clayton DG, Cardon LR, Craddock N, et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet 2007;39:1329-1337. https://doi.org/10.1038/ng.2007.17
- Evans DM, Spencer CC, Pointon JJ, Su Z, Harvey D, Kochan G, et al. Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Nat Genet 2011;43:761-767. https://doi.org/10.1038/ng.873
- Lin Z, Bei JX, Shen M, Li Q, Liao Z, Zhang Y, et al. A genome-wide association study in Han Chinese identifies new susceptibility loci for ankylosing spondylitis. Nat Genet 2011;44:73-77.
- Australo-Anglo-American Spondyloarthritis Consortium (TASC), Reveille JD, Sims AM, Danoy P, Evans DM, Leo P, et al. Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci. Nat Genet 2010;42:123-127. https://doi.org/10.1038/ng.513
- Jung SH, Yim SH, Hu HJ, Lee KH, Lee JH, Sheen DH, et al. Genome-wide copy number variation analysis identifies deletion variants associated with ankylosing spondylitis. Arthritis Rheumatol 2014;66:2103-2112. https://doi.org/10.1002/art.38650
- Haroon N, Inman RD, Learch TJ, Weisman MH, Lee M, Rahbar MH, et al. The impact of tumor necrosis factor alpha inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum 2013;65:2645-2654.
- Sieper J, Rudwaleit M. How early should ankylosing spondylitis be treated with tumour necrosis factor blockers? Ann Rheum Dis 2005;64 Suppl 4:iv61-iv64.
- Wallis D, Inman RD. Recognition of preclinical and early disease in axial spondyloarthritis. Rheum Dis Clin North Am 2014;40:685-697. https://doi.org/10.1016/j.rdc.2014.07.011
- Jung SH, Cho SM, Yim SH, Kim SH, Park HC, Cho ML, et al. Developing a risk-scoring model for ankylosing spondylitis based on a combination of HLA-B27, single-nucleotide polymorphism, and copy number variant markers. J Rheumatol 2016;43:2136-2141. https://doi.org/10.3899/jrheum.160347
- Lian Z, Chai W, Shi LL, Chen C, Liu J, Wang Y. Analysis of PPARGC1B, RUNX3 and TBKBP1 polymorphisms in Chinese Han patients with ankylosing spondylitis: a case-control study. PLoS One 2013;8:e61527. https://doi.org/10.1371/journal.pone.0061527
- Zhang L, Fan D, Liu L, Yang T, Ding N, Hu Y, et al. Association study of IL-12B polymorphisms susceptibility with ankylosing spondylitis in mainland Han population. PLoS One 2015;10:e0130982. https://doi.org/10.1371/journal.pone.0130982
- van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-368. https://doi.org/10.1002/art.1780270401
- Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007;81:559-575. https://doi.org/10.1086/519795
- Woolf E, Xiao C, Fainaru O, Lotem J, Rosen D, Negreanu V, et al. Runx3 and Runx1 are required for CD8 T cell development during thymopoiesis. Proc Natl Acad Sci U S A 2003;100:7731-7736. https://doi.org/10.1073/pnas.1232420100
- Fainaru O, Woolf E, Lotem J, Yarmus M, Brenner O, Goldenberg D, et al. Runx3 regulates mouse TGF-beta-mediated dendritic cell function and its absence results in airway inflammation. EMBO J 2004;23:969-979. https://doi.org/10.1038/sj.emboj.7600085
- Apel M, Uebe S, Bowes J, Giardina E, Korendowych E, Juneblad K, et al. Variants in RUNX3 contribute to susceptibility to psoriatic arthritis, exhibiting further common ground with ankylosing spondylitis. Arthritis Rheum 2013;65:1224-1231. https://doi.org/10.1002/art.37885
- Wang W, Ma Y, Xu Y, Sheng Y, Gao J, Zuo X, et al. RUNX3 gene polymorphisms are associated with clinical features of systemic lupus erythematosus in Chinese Han population. J Dermatol Sci 2015;80:69-71. https://doi.org/10.1016/j.jdermsci.2015.07.005
- Vecellio M, Roberts AR, Cohen CJ, Cortes A, Knight JC, Bowness P, et al. The genetic association of RUNX3 with ankylosing spondylitis can be explained by allele-specific effects on IRF4 recruitment that alter gene expression. Ann Rheum Dis 2016;75:1534-1540. https://doi.org/10.1136/annrheumdis-2015-207490
Cited by
- The Early Phases of Ankylosing Spondylitis: Emerging Insights From Clinical and Basic Science vol.9, pp.1664-3224, 2018, https://doi.org/10.3389/fimmu.2018.02668
- ERAP1/ERAP2 and RUNX3 polymorphisms are not associated with ankylosing spondylitis susceptibility in Chinese Han vol.193, pp.1, 2018, https://doi.org/10.1111/cei.13121